Detalles de la búsqueda
1.
A multicenter, randomized, open-label, 2-arm parallel study to compare the pharmacokinetics, safety and tolerability of AVT02 administered subcutaneously via prefilled syringe or autoinjector in healthy adults.
Expert Opin Biol Ther
; 23(8): 773-780, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36197309
2.
Assessing the Interchangeability of AVT02 and Humira® in Participants with ModeratetoSevere Chronic Plaque Psoriasis: Pharmacokinetics, Efficacy, Safety, and Immunogenicity Results from a Multicenter, Double-Blind, Randomized, Parallel-Group Study.
BioDrugs
; 37(4): 551-567, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37204631
3.
Assessment of real-life patient handling experience of AVT02 administered subcutaneously via autoinjector in patients with moderate to severe active rheumatoid arthritis: an open-label, single-arm clinical trial, then an extension phase of AVT02 administered with a prefilled syringe.
Expert Opin Biol Ther
; 23(8): 781-789, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36205514
4.
A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Expert Opin Investig Drugs
; 31(9): 965-976, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35107050
5.
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study.
BioDrugs
; 35(6): 735-748, 2021 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-34657274
Resultados
1 -
5
de 5
1
Próxima >
>>